MPM Bioimpact LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
MPM Bioimpact LLC disclosed 47 US equity positions worth $704.4m in its Q4 2024 13F filing. The largest position was CGEM at 13.2% of the reported book, followed by CRNXGBP and EWTX. Against the Q3 2024 filing, it opened 11 new positions, added to 21 and reduced 11 among the top 47 holdings.
What did MPM Bioimpact LLC own in Q4 2024? Top 47 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | CGEM Cullinan Therapeutics, Inc. | Healthcare | 13.2% | $93.2m | 7,648,268 | 0% | held |
| 2 | CRNXGBP Crinetics Pharmaceuticals Inc. | 4.5% | $31.5m | 617,035 | 17% | added | |
| 3 | EWTX Edgewise Therapeutics Inc | 4.1% | $28.8m | 1,079,316 | 18% | added | |
| 4 | INSM Insmed Incorporated | Healthcare | 3.8% | $26.9m | 389,611 | -37% | reduced |
| 5 | NTRA Natera Inc | Healthcare | 3.6% | $25.4m | 160,626 | -9% | reduced |
| 6 | MIRM Mirum Pharmaceuticals Inc | Healthcare | 3.5% | $24.4m | 589,579 | 20% | added |
| 7 | IRON Disc Medicine Inc | Healthcare | 3.1% | $22.0m | 346,401 | 11% | added |
| 8 | LNTH Lantheus Holdings Inc | Healthcare | 3.0% | $21.1m | 236,213 | 57% | added |
| 9 | ZLAB Zai Lab Ltd | Healthcare | 3.0% | $21.0m | 800,000 | – | new |
| 10 | RNAGBP Avidity Biosciences Inc | 2.9% | $20.4m | 702,981 | 2% | added | |
| 11 | IOVA Iovance Biotherapeutics Inc | Healthcare | 2.8% | $19.8m | 2,673,905 | 11% | added |
| 12 | PTCT PTC Therapeutics Inc | Healthcare | 2.8% | $19.6m | 434,767 | 385% | added |
| 13 | WVE Wave Life Sciences PTE LTD | Healthcare | 2.6% | $18.4m | 1,489,237 | 138% | added |
| 14 | SRRK Scholar Rock Holding Corp. | Healthcare | 2.6% | $18.0m | 416,144 | – | new |
| 15 | MLTX Moonlake Immunotherapeutics | Healthcare | 2.4% | $17.1m | 315,230 | -10% | reduced |
| 16 | OLMA Olema Pharmaceuticals, Inc. | Healthcare | 2.4% | $17.0m | 2,912,550 | 9% | added |
| 17 | RARE Ultragenyx Pharmaceutical Inc | Healthcare | 2.3% | $16.5m | 391,018 | 19% | added |
| 18 | CNTX Context Therapeutics Inc | 2.2% | $15.4m | 14,705,882 | – | new | |
| 19 | GH Guardant Health Inc | Healthcare | 2.0% | $13.8m | 452,739 | -9% | reduced |
| 20 | RVMD Revolution Medicines, Inc. | Healthcare | 1.9% | $13.7m | 313,817 | 8% | added |
| 21 | 2662247D iTeos Therapeutics, Inc. | 1.9% | $13.4m | 1,745,943 | 0% | held | |
| 22 | RNAC Cartesian Therapeutics Inc | 1.8% | $12.9m | 721,139 | 15% | added | |
| 23 | RCKT Rocket Pharmaceuticals, Inc. | Healthcare | 1.8% | $12.8m | 1,020,559 | -4% | reduced |
| 24 | Akero Therapeutics Inc | 1.8% | $12.8m | 460,617 | 17% | added | |
| 25 | TRVI Trevi Therapeutics Inc | Healthcare | 1.8% | $12.8m | 3,094,896 | 101% | added |
| 26 | TWST Twist Bioscience Corp | Healthcare | 1.8% | $12.4m | 267,497 | -9% | reduced |
| 27 | CMPX Compass Therapeutics, Inc. | 1.8% | $12.4m | 8,567,896 | 52% | added | |
| 28 | JANX Janux Therapeutics Inc | Healthcare | 1.7% | $12.3m | 230,000 | 34% | added |
| 29 | REPL Replimune Group Inc | Healthcare | 1.6% | $11.5m | 950,000 | – | new |
| 30 | NUVB Nuvation Bio Inc | Healthcare | 1.6% | $11.1m | 4,164,178 | – | new |
| 31 | VERA Vera Therapeutics Inc. | Healthcare | 1.5% | $10.9m | 257,788 | – | new |
| 32 | IDYA Ideaya Biosciences, Inc. | Healthcare | 1.5% | $10.6m | 414,035 | – | new |
| 33 | RLAY Relay Therapeutics Inc. | Healthcare | 1.3% | $9.3m | 2,268,825 | 12% | added |
| 34 | UTHR United Therapeutics Corp. | Healthcare | 1.2% | $8.1m | 23,000 | – | new |
| 35 | ARCT Arcturus Therapeutics Holdings | Healthcare | 1.1% | $7.8m | 459,943 | 110% | added |
| 36 | XENE Xenon Pharmaceuticals Inc | Healthcare | 1.1% | $7.7m | 197,212 | 19% | added |
| 37 | STOK Stoke Therapeutics Inc | Healthcare | 1.1% | $7.6m | 685,826 | 43% | added |
| 38 | AQST Aquestive Therapeutics Inc | 0.8% | $5.7m | 1,611,833 | -10% | reduced | |
| 39 | AXSM Axsome Therapeutics Inc | Healthcare | 0.6% | $4.2m | 50,000 | – | new |
| 40 | STRO Sutro Biopharma, Inc. | Healthcare | 0.6% | $4.0m | 2,160,062 | -24% | reduced |
| 41 | HOWL Werewolf Therapeutics, Inc. | 0.5% | $3.5m | 2,388,011 | 0% | held | |
| 42 | DSGN Design Therapeutics Inc | Healthcare | 0.5% | $3.5m | 559,547 | – | new |
| 43 | ZNTL Zentalis Pharmaceuticals, Inc. | Healthcare | 0.5% | $3.4m | 1,106,851 | -24% | reduced |
| 44 | VERU Veru Inc. | Healthcare | 0.4% | $2.8m | 4,285,365 | – | new |
| 45 | ADAPY Adaptimmune Therapeutics plc | Healthcare | 0.4% | $2.7m | 5,095,912 | 0% | held |
| 46 | ALXO ALX Oncology Holdings Inc. | Healthcare | 0.3% | $2.3m | 1,391,434 | -42% | reduced |
| 47 | RPTX Repare Therapeutics, Inc. | 0.2% | $1.6m | 1,231,154 | -25% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.